Skip to main content

Advertisement

Log in

A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The objective of this study was to identify predictors for remission or low disease activity (LDA) in established rheumatoid arthritis (RA) at 12 months of anti-TNF-α therapy. We have performed a prospective observational study in 90 consecutive patients with active RA receiving TNF-α inhibitors. Baseline and standard assessments were done every 3 months, including individual parameters (clinical and biological) and composite activity scores (28-joint disease activity score, DAS28). The primary outcome measure was DAS28-based EULAR response criteria. The multivariate logistic regression was used to analyze the association between disease activity and several RA baseline characteristics. Of the RA, 78.8 % was classified as good responders based on the EULAR-DAS28 criteria, 44.4 % RA achieving remission (DAS28 ≤ 2.6) and 34.4 %, LDA (DAS28 ≤ 3.2). Parameters associated with an increased likelihood of remission and LDA were initial DAS28-erythrocyte sedimentation rate ≤7 (odds ratio (OR) 3.3, 95 % confidence interval (CI) 2.03–5.81; OR 1.8, 95 % CI 1.09–6.68), Health Assessment Questionnaire Disability Index ≤ 2 (OR 7.0, 95 % CI 1.56–31.91; OR 1.3, 95 % CI 1.03–5.79), C-reactive protein level ≤20 mg/l (OR 1.5, 95 % CI 0.29–8.22; OR 0.5, 95 % CI0.08–2.97), rheumatoid factor ≤20 IU/ml (OR 18.9, 95 % CI 10.79–38.36; OR 32.9, 95 % CI 4.03–269), anti-cyclic citrullinated peptide antibodies ≤40 IU/ml (OR 3.5, 95 % CI 0.67–18.19; OR 1.2, 95 % CI 1.02–1.59), concurrent prednisolone (OR 0.2, 95 % CI 0.05–0.36; OR 0.2, 95 % CI 0.06–0.63), methotrexate or leflunomide (OR 1.6, 95 % CI 1.2–13.53; OR 2.9, 95 % CI 1.20–4.36). A predictive matrix for remission and LDA in established active RA patients receiving TNF-α inhibitors was proposed. Further studies are necessary to confirm the value of such matrix in particular RA settings, leading to optimization of the use of anti-TNF-α therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Luqmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, Fokke C, Goodson N, Jeffreson P, Lamb E, Mohammed R, Oliver S, Stableford Z, Walsh D, Washbrook C, Webb F, British Society for Rheumatology, British Health Professionals in Rheumatology Standards Guidelines and Audit Working Group (2006) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford) 45:1167–1169

    Article  CAS  Google Scholar 

  2. Bykerk V, Keystone E (2005) What are the goals and principles of management in the early treatment of rheumatoid arthritis. Best Pract Res ClinRheumatol 19:147–161

    Article  Google Scholar 

  3. Fransen J, Moens HB, Speyer I, van Riel PL (2005) Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomized controlled trial. Ann Rheum Dis 64:1294–1298

    Article  PubMed  CAS  Google Scholar 

  4. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ et al (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer assisted management in early rheumatoid arthritis (camera, an open-label strategy trial). Ann Rheum Dis 66:1443–1449

    Article  PubMed  CAS  Google Scholar 

  5. Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F et al (2011) Group for respect of ethics and excellence in science (grees). Biomarkers and personalized medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis 70(10):1713–1718

    Article  PubMed  CAS  Google Scholar 

  6. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W et al (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10:1–229, iii–iv, xi–xiii

    Google Scholar 

  7. Marotte H, Miossec P (2010) Biomarkers for prediction of TNFα blockers response in rheumatoid arthritis. Joint Bone Spine 77:297–05

    Article  PubMed  CAS  Google Scholar 

  8. Mader R, Keystone E (2007) Optimizing treatment with biologics. J Rheumatol Suppl 80:16–24

    PubMed  CAS  Google Scholar 

  9. Erickson AR, Mikuls TR (2007) Switching anti–TNF-alpha agents: what is the evidence. CurrRheumatol Rep 9(5):416–420

    Article  CAS  Google Scholar 

  10. Bolosiu H, Ionescu R, Chirieac R, Georgescu L, Rednic S, Suta M, et al. (2011) Ghidul de tratament al poliartriteireumatoide. RevistaRomană de Reumatologie vol. xx nr. 1; 36–53.

  11. van Gestel AM, Prevoo ML, van Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 39:34–40

    Article  PubMed  Google Scholar 

  12. Katchamart W, Johnson S, Lin H, Phumethum V, Salliot C, Bombardier C (2010) Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res 62:1128–1143

    Article  Google Scholar 

  13. Vazquez I, Graell E, Gratacos J, Canete JD, Vinas O, Ercilla MG et al (2007) Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting. ClinExpRheumatol 25:231–238

    CAS  Google Scholar 

  14. Forslind K, Hafstrom I, Ahlmen M, Svensson B (2007) The BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis. Ann Rheum Dis 66:46–52

    Article  PubMed  CAS  Google Scholar 

  15. Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Saez I, Unnebrink K, Kary S et al (2008) Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. Arthritis Rheum 59:32–41

    Article  PubMed  CAS  Google Scholar 

  16. Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P (2008) Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish arthritis treatment group register. Rheumatology (Oxford) 47:495–499

    Article  CAS  Google Scholar 

  17. Verstappen SM, van Albada-Kuipers GA, Bijlsma JW, Blaauw AA, Schenk Y, Haanen HC et al (2005) A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 64:38–43

    Article  PubMed  CAS  Google Scholar 

  18. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D et al (2007) Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-α blockers: the GISEA study. J Rheumatol 34:1670–1673

    PubMed  CAS  Google Scholar 

  19. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J (2002) For the FIN-RACo Trial Group. Delay to institution of therapy and induction of remission using singledrug or combination–disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 46:894–898

    Article  PubMed  CAS  Google Scholar 

  20. Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register (2006) Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45:1558–1565

    Article  CAS  Google Scholar 

  21. Van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P (2007) For the TEMPO Study Investigators. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56:3928–3939

    Article  PubMed  Google Scholar 

  22. Molenaar ET, Voskuyl AE, van der Horst-Bruinsma IE, Schreuder GM, Zanelli E, Dijkmans BA (2002) Influence of HLA polymorphism on persistent remission in rheumatoid arthritis. Ann Rheum Dis 61:351–353

    Article  PubMed  CAS  Google Scholar 

  23. Hyrich KL, Symmons DP, Watson KD, Silman AJ, British Society for Rheumatology Biologics Register (2006) Comparison of the response to infliximab or etanerceptmonotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:1786–1794

    Article  PubMed  CAS  Google Scholar 

  24. Liang GC, Cordero M, Dyer A, Chang RW (2005) Current tumor necrosis factor-α inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis. J Rheumatol 32:1662–1665

    PubMed  CAS  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Codrina Ancuta.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pomirleanu, C., Ancuta, C., Miu, S. et al. A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers. Clin Rheumatol 32, 665–670 (2013). https://doi.org/10.1007/s10067-012-2146-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-012-2146-6

Keywords

Navigation